Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Chase Pharmaceuticals logo — Pioneering advancements in neuropsychiatric treatment for a...

Chase Pharmaceuticals

Pioneering advancements in neuropsychiatric treatment for a brighter future

Founded 2007 11-50 employees Series B Total: $28.70M Biotechnology, Health Care

General Information

Company Name Chase Pharmaceuticals
Founded Year 2007
Employees 11-50
Industries Biotechnology, Health Care
Funding Stage Series B
Social

BounceWatch is an independent company data service, not affiliated with Chase Pharmaceuticals. To contact Chase Pharmaceuticals, visit chasepharmaceuticals.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Chase Pharmaceuticals compare?

A PDF of Chase Pharmaceuticals and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Chase Pharmaceuticals soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Chase Pharmaceuticals

Chase Pharmaceuticals (CPC) has been pioneering advancements in neuropsychiatric treatment since its establishment in 2007. The company's focus on identifying and developing promising treatments for central nervous system (CNS) diseases aligns with the critical medical needs of neuropsychiatric patients. CPC's operations involve selecting, licensing-in, advancing, and licensing-out drug candidates for commercial partners, with a strong emphasis on effective selection, deep developmental knowledge, and efficient regulatory strategies. The significant unmet need in neuropsychiatry, particularly within Alzheimer's disease (AD) and related neurodegenerative disorders, serves as CPC's primary target. AD, affecting approximately 37 million people globally, poses a substantial burden estimated at over $600 billion annually. Despite AD medication sales reaching $4.7 billion, current treatments offer only marginal symptom improvement, with poor tolerability and high dropout rates. In 2016, CPC secured a $3.50M Series B investment, showcasing investor confidence in its potential to address critical unmet needs in neuropsychiatric treatment. The company's innovative approach of inventing and patenting a unique combination of existing pharmaceuticals for the symptomatic treatment of AD demonstrates commitment to addressing the global burden of CNS diseases. Chase Pharmaceuticals' efforts present a compelling opportunity in the biotechnology and healthcare industries, aiming for a brighter future in neuropsychiatric treatment.

Business keywords: neuropsychiatric treatment, CNS diseases, Alzheimer's disease, neurodegenerative disorders, pharmaceutical research, drug development, clinical trials, medical innovation, neuroscience, regulatory approval, pharmaceutical patents, symptomatic treatment, innovative therapies, healthcare advancements

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series B $3.50M -
18 Feb 2016
Venture Round $3.00M -
20 Aug 2015
Series B $21.00M 3
Andera Partner New Rhein Healthcare Investors
Andera Partner, New Rhein Healthcare Investors +1
12 May 2014
Series A $1.20M 1
Brain Trust Accelerator Fund
Brain Trust Accelerator Fund
15 Dec 2010

Chase Pharmaceuticals Alternatives & Competitors

View All Alternatives
Chase Pharmaceuticals vs
Neumora
Neumora United States

Pioneering a new era of medicines for brain diseases

Series B
111 employees
Biotechnology, Health Care
Chase Pharmaceuticals vs
Myrobalan Therapeutics
Myrobalan Therapeutics United States

Myro’s mission is to develop first-in-class and best-in-class small molecule drugs for CNS disorders...

Grant
27 employees
Biotechnology, Health Care
Chase Pharmaceuticals vs
Merck & Co., Inc.
Merck & Co., Inc.

Merck develops and produces medicines, vaccines, biologic therapies and animal health products

IPO
92 employees
Biotechnology, Health Care
View all alternatives

FAQ About Chase Pharmaceuticals

Pioneering advancements in neuropsychiatric treatment for a brighter future
Chase Pharmaceuticals was founded in 2007.
Chase Pharmaceuticals operates in Biotechnology and Health Care. Its work centres on neuropsychiatric treatment, CNS diseases, Alzheimer's disease and neurodegenerative disorders.
Chase Pharmaceuticals has approximately 11-50 employees.
Chase Pharmaceuticals has completed 4 funding rounds, raising a total of $28.70M. The latest funding stage is Series B.
Top alternatives and competitors to Chase Pharmaceuticals include Neumora, Myrobalan Therapeutics, Merck & Co., Inc., CaSRevolution, Amyl Therapeutics. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Chase Pharmaceuticals and Neumora are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Chase Pharmaceuticals, https://bouncewatch.com/company/chase-pharmaceuticals, updated 10 October 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes